Prof Max Topp talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about the Bispecific T-cell engaging therapy for adult ALL patients.

Prof Topp states that following approvals the drug is now available around the globe and that it is complemented by other newly developed therapies.

He goes on to say how this bispecific technology could be used across haematology oncology but also in other areas.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.